Skip to Content

SODIUM LACTATE INJECTION USP

View full screen / Print PDF » Download PDF ⇩

PDF Transcript

PRODUCT SUMMARY
1. Trade name of the medicinal product
NORSK - NO DATA
2. Qualitative and quantitative composition
NORSK - NO DATA
3. Pharmaceutical form
NORSK - NO DATA

4. CLINICAL PARTICULARS
4.1 Therapeutic indicators
FOR ADMINISTRATION BY INTRAVENOUS INFUSION.
4.2 Posology and method of administration
THE DOSAGE OF SODIUM LACTATE INTRAVENOUS INFUSION IS DEPENDANT UPON THE
AGE, WEIGHT AND CLINICAL CONDITIONS OF THE PATIENT.
4.3/4.9 Clinical particulars section
A) CONTRAINDICATIONS: PATIENTS WITH SEVERE LIVER DAMAGE WITH AN
IMPAIRMENT OF LACTATE UTILISATION. PATIENTS WHO HAVE AN IMPAIRED
ABILITY TO HANDLE SODIUM SUCH AS ORGANIC DISEASE, ESPECIALLY WITH A
HISTORY OF CONGESTIVE HEART FAILURE, PATIENTS WITH RENAL INSUFFICIENCY,
CIRRHOSIS OF THE LIVER, CARDIOPULMONARY DISEASE OR PATIENTS RECEIVING
SALT-RETAINING STEROIDS.
B) INTERACTIONS WITH OTHER MEDICAMENTS: NONE STATED
C) EFFECTS ON ABILITY TO DRIVE AND USE MACHINES: NONE STATED
D) OTHER UNDESIRABLE EFFECTS: PROLONGED INTRAVENOUS INFUSION MAY CAUSE
THROMBOPHLEBITIS EXTENDING FROM THE SITE OF INFUSION.
E) USE I N PREGNANCY AND LACTATION: NONE STATED
F) OTHER SPECIAL WARNINGS AND PRECAUTIONS:
I)
ADMINISTER WITH CAUTION IN ALL PATIENTS TO AVOID METABOLIC
ALKALOSIS RESULTING FROM EXCESS ADMINISTRATION.
II) ADMINISTER WITH CAUTION TO PATIENTS WITH DECOMPENSATED
CARDIOVASCULAR, CIRRHOTIC AND NEPHROTIC DISEASE AND TO PATIENTS
RECEIVING CORTICOSTEROIDS OR CORTICOTROPHIN.
III) THE SOLUTION SHOULD NOT BE USED UNLESS IT IS CLEAR AND THE
CONTAINER UNDAMAGED.
G) OVERDOSE: DISCONTINUE INFUSION IF ADVERSE REACTION OCCURS.
H) INCOMPATIBILITIES: COMPATIBILITIES SHOULD BE CHECKED WHEN ADDITIVES
ARE USED.

5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
NORSK - NO DATA
5.2 Pharmacokinetic properties
NORSK - NO DATA

PHARMACEUTICAL PROPERTIES
6.1 List of excipients
NORSK - NO DATA
6.2 Incompatibilites
NORSK - NO DATA
6.3 Shelf life
NORSK - NO DATA
6.4 Special precautions for storage
NORSK - NO DATA
6.5 Nature and contents of container
NORSK - NO DATA
6.6 Instructions for use/handling
NORSK - NO DATA

ADMINISTRATION DETAILS
7. Marketing authorization holder
NORSK - NO DATA
8. Marketing Authorization number
NORSK - NO DATA
9. Date of first authorization/renewal of authorization
NORSK - NO DATA
10. Date of (partial) revision of the text
NORSK - NO DATA

Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide